Editorials

Filter By:

Article Type
  • The International Society for Stem Cell Research has called for broad public dialogue on the ethics of human embryo research beyond 14 days post-fertilization. National jurisdictions should seize the moment.

    Editorial
  • An Alzheimer’s drug approval is being touted as a triumph for patients. But US healthcare is ill prepared for Aduhelm’s questionable efficacy, unfettered market access and high price.

    Editorial
  • New initiatives in N-of-1 drug development and clinical trial design offer the possibility of therapies for ultra-rare disease patients who have been long neglected by the drug industry.

    Editorial
  • To keep ahead of an increasing number of SARS-CoV-2 variants, pathogen surveillance and testing must become a joined-up global, rather than local, endeavor.

    Editorial
  • The US RADx program has spawned a phalanx of diagnostic products to market in just 12 months. Its long-term impact on point-of-care, at-home and population testing may be even more profound.

    Editorial
  • Since this journal launched in March 1996, biotech has become a US economic powerhouse. To reach its full potential over the next 25 years, touching all corners of the globe, it must become more inclusive.

    Editorial
  • With drug pricing a priority for the US Biden administration, the biotech industry must clean up its act: stop profiteering from old products and stamp out anticompetitive practices.

    Editorial
  • Emergency Use Authorizations for two mRNA COVID-19 vaccines represent a turning point in the pandemic. They also herald a new era for vaccinology.

    Editorial
  • Rapid progress is being made in our understanding of RNA–protein interactions, their role in disease and their influence on the action of oligonucleotide drugs.

    Editorial
  • Clear and consistent messaging on COVID-19 vaccine rollout will be key to building public trust and managing expectations.

    Editorial
  • The scientific integrity of US government agencies is under attack from the Trump administration. Agency senior executives and industry leaders need to continue pushing back.

    Editorial
  • The pandemic has highlighted long-standing, deep-rooted challenges to the sharing of biological samples. Greater attention is needed to mechanisms for incentivizing materials transfer.

    Editorial
  • As preliminary research findings are shared more widely and at an increasing pace, action is needed to counter the spread of misinformation.

    Editorial
  • As CRISPR–Cas9 enters human testing, the blistering pace of progress in preclinical research is offering a bewildering array of options for therapeutic gene editing.

    Editorial
  • A slew of national COVID-19 exposure apps have failed because of poor public engagement and acceptance. Apps from the workplace may offer a partial solution if privacy can be guaranteed.

    Editorial
  • Insufficient SARS-CoV-2 testing has left many nations flying blind as they reopen their economies. Without adequate testing, new infections could outrun control measures.

    Editorial
  • COVID-19 has reinforced the importance of preprints as an indispensable means for rapid research dissemination.

    Editorial
  • In the onslaught of the COVID-19 pandemic, the open sharing of materials, information and data is gaining increasing importance in biotech.

    Editorial
  • In the post-Brexit era, Britain must rapidly harmonize national and European law, secure unfettered access to global talent and address funding shortfalls to ensure continued leadership in the life sciences.

    Editorial
  • The US Food and Drug Administration is sticking to its plan to carry out mandatory premarket review of all gene-edited livestock, irrespective of trait risk. It should rethink.

    Editorial